Lite Strategy, Inc. (LITS): R&D Expense
$3.92M
Year ended 2025-06-30
$169.0K
Trailing 12 months to 2026-03-31
-64.2%
3-year compound annual growth
-35.1%
5-year compound annual growth
-16.5%
10-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-06-30 | $3.92M | -76.3% | 2025-09-26, From 2024-07-01 |
| 2024-06-30 | $16.56M | -68.4% | 2025-09-26, From 2023-07-01 |
| 2023-06-30 | $52.45M | -38.8% | 2024-09-19, From 2022-07-01 |
| 2022-06-30 | $85.64M | +23.4% | 2023-09-26, From 2021-07-01 |
| 2021-06-30 | $69.40M | +103.7% | 2022-09-08, From 2020-07-01 |
| 2020-06-30 | $34.06M | +5.5% | 2022-09-08, From 2019-07-01 |
| 2019-06-30 | $32.30M | +89.6% | 2022-05-23, From 2018-07-01 |
| 2018-06-30 | $17.04M | +135.4% | 2020-09-09, From 2017-07-01 |
| 2017-06-30 | $7.24M | -46.0% | 2019-08-28, From 2016-07-01 |
| 2016-06-30 | $13.40M | -43.7% | 2018-08-30, From 2015-07-01 |
| 2015-06-30 | $23.82M | +23.2% | 2017-09-05, From 2014-07-01 |
| 2014-06-30 | $19.33M | +217.7% | 2016-09-06, From 2013-07-01 |
| 2013-06-30 | $6.08M | +23.8% | 2015-09-02, From 2012-07-01 |
| 2012-06-30 | $4.92M | +132.4% | 2014-09-09, From 2011-07-01 |
| 2011-06-30 | $2.12M | n/a | 2012-09-18, From 2010-07-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Lite Strategy, Inc. (LITS) | 2025-06-30 | $3.92M | -76.3% |
| Abbott Laboratories (ABT) | 2025-12-31 | $2.94B | +3.4% |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $9.95B | -10.8% |
| Eli Lilly & Co (LLY) | 2025-12-31 | $13.34B | +21.3% |
| Pfizer Inc (PFE) | 2025-12-31 | $10.44B | -3.6% |
| Johnson & Johnson (JNJ) | 2025-12-28 | $14.66B | -14.9% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $1.90M | +11.8% |
| Merck & Co., Inc. (MRK) | 2025-12-31 | $15.79B | -12.0% |
| Provectus Biopharmaceuticals, Inc. (PVCT) | 2025-12-31 | $1.90M | -7.5% |
Compare LITS, ABT, BMY, LLY side by side · Screen every company in Pharmaceutical Preparations ↗